Home » Newsletters » BioWorld Science

BioWorld Science

March 8, 1999

View Archived Issues

Aviron: Q4 1998 highlights

NeoRx: Q4 1998 highlights

Viragen: Q2 1998 highlights

Agouron solves structure of key target for drugs to block angiogenesis

Hemosol successfully completes phase II trial of Hemolink in CABG patients

Uncompetitive NMDA antagonists show improved efficacy in Parkinson's disease models

Novel AD and metabolic syndrome targets as focus of Exelixis and P&U collaboration

Spotlight on agents for peripheral vascular disease

New anticancer agents from LG Chemical inhibit farnesyltransferase

Antithrombotic P2T antagonists in development at Astra

Muscarinic receptor modulators for psychotic disorders patented by Lilly

Bupropion more effective than nicotine patches in smoking cessation therapy

Merck discloses novel endothelin receptor antagonists

Chemokine receptor modulators from Merck & Co. described in recent patent literature

Cyclooxygenase-inhibitory indoles under study at Pfizer

Texas Biotechnology: Q4 and year-end 1998 results

Na+/Ca2+ exchange inhibitor provides effective neuroprotection in vitro

Findings from burn study demonstrate advantage of Apligraf + autograft versus autograft alone

Study suggests potential of MS-325 in blood pool imaging

diaDexus's first diagnostic product licensed to SmithKline Beecham unit

Pharmacia & Upjohn and Centocor to copromote Fragmin in unstable angina

Bio-Technology General receives added patent protection for novel anticoagulant

FDA approves controlled-release form of popular antidepressant

North American Vaccine adds new product to R&D pipeline; U.S. patent issues

Xenova reveals structure of P-gp-mediated MDR modulators, including clinical compound XR-9576

Microbial metabolite inhibits ICAM-1/LFA-1-mediated cell adhesion

Microbial fatty acid enhances endothelial cell fibrinolytic activity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...